Mahdjoubi A, et al. - Researchers undertook this analysis to assess the efficacy of bevacizumab on reduction of the enucleation rate and control of intraocular pressure (IOP) in neovascular glaucoma (NVG)-complicating proton beam therapy for UM. Furthermore, determinants of bevacizumab's efficacy were also investigated. Intravitreal bevacizumab (IVB) improved IOP level but failed to cause attenuation in the overall enucleation rate in NVG following proton beam therapy. Nevertheless, this treatment displayed efficacy in the early phases of NVG or as a preventive treatment. For NVG, panretinal photocoagulation (PRP) continued to be a valid treatment.